{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:53:32Z","timestamp":1773687212786,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Horizon Pharma USA, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40744-018-0111-9","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T10:06:45Z","timestamp":1525342005000},"page":"583-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases"],"prefix":"10.1007","volume":"5","author":[{"given":"Allan H.","family":"Morton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Hosey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,3]]},"reference":[{"key":"111_CR1","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheumatol. 2011;63:3136\u201341.","journal-title":"Arthritis Rheumatol"},{"key":"111_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"PP Khanna","year":"2012","unstructured":"Khanna PP, Nuki G, Bardin T, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10:117.","journal-title":"Health Qual Life Outcomes"},{"key":"111_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/SMJ.0000000000000082","volume":"107","author":"E Karis","year":"2014","unstructured":"Karis E, Crittenden DB, Pillinger MH. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street. South Med J. 2014;107:235\u201341.","journal-title":"South Med J"},{"key":"111_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/RHU.0000000000000561","volume":"23","author":"BW Coburn","year":"2017","unstructured":"Coburn BW, Bendlin KA, Sayles H, Meza J, Russell CL, Mikuls TR. Allopurinol medication adherence as a mediator of optimal outcomes in gout management. J Clin Rheumatol. 2017;23:317\u201323.","journal-title":"J Clin Rheumatol"},{"key":"111_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1742395310378761","volume":"6","author":"LR Harrold","year":"2010","unstructured":"Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010;6:263\u201371.","journal-title":"Chronic Illn"},{"key":"111_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10067-013-2168-8","volume":"32","author":"PC Robinson","year":"2013","unstructured":"Robinson PC, Schumacher HR Jr. A qualitative and quantitative analysis of the characteristics of gout patient education resources. Clin Rheumatol. 2013;32:771\u20138.","journal-title":"Clin Rheumatol"},{"key":"111_CR7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/art.22232","volume":"55","author":"F Perez-Ruiz","year":"2006","unstructured":"Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheumatol. 2006;55:786\u201390.","journal-title":"Arthritis Rheumatol"},{"key":"111_CR8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3899\/jrheum.111375","volume":"39","author":"V Strand","year":"2012","unstructured":"Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012;39:1450\u20137.","journal-title":"J Rheumatol"},{"key":"111_CR9","unstructured":"Krystexxa\u00ae (pegloticase injection), for intravenous infusion: US prescribing information. Lake Forest, IL: Horizon Pharma USA, Inc.; 2016."},{"key":"111_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1617","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711\u201320.","journal-title":"JAMA"},{"key":"111_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","volume":"60","author":"MR Sherman","year":"2008","unstructured":"Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008;60:59\u201368.","journal-title":"Adv Drug Deliv Rev"},{"key":"111_CR12","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1002\/art.23810","volume":"58","author":"JS Sundy","year":"2008","unstructured":"Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheumatol. 2008;58:2882\u201391.","journal-title":"Arthritis Rheumatol"},{"key":"111_CR13","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/ar4318","volume":"15","author":"HS Baraf","year":"2013","unstructured":"Baraf HS, Becker MA, Gutierrez-Urena SR, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013;15:R137.","journal-title":"Arthritis Res Ther"},{"key":"111_CR14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","volume":"72","author":"MA Becker","year":"2013","unstructured":"Becker MA, Baraf HS, Yood RA, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013;72:1469\u201374.","journal-title":"Ann Rheum Dis"},{"key":"111_CR15","first-page":"2070","volume":"69","author":"N Schlesinger","year":"2017","unstructured":"Schlesinger N, Khanna P, Yeo A, Lipsky PE. Evidence-based development of criteria for complete response in patients with chronic refractory gout. Arthritis Rheumatol. 2017;69:2070.","journal-title":"Arthritis Rheumatol"},{"key":"111_CR16","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/annrheumdis-2017-eular.5365","volume":"76","author":"H Baraf","year":"2017","unstructured":"Baraf H, Morton A, LaMoreaux B, Kent J. Pegloticase re-treatment after a gap in therapy: data from two phase III trials nad an open-label extension study. Ann Rheum Dis. 2017;76:1360.","journal-title":"Ann Rheum Dis"},{"key":"111_CR17","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431\u201346.","journal-title":"Arthritis Care Res"},{"key":"111_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1759720X16646703","volume":"8","author":"SE Sattui","year":"2016","unstructured":"Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016;8:145\u201359.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"111_CR19","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1185\/03007995.2010.533647","volume":"26","author":"RA Brook","year":"2010","unstructured":"Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin. 2010;26:2813\u201321.","journal-title":"Curr Med Res Opin"},{"key":"111_CR20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64:1447\u201361.","journal-title":"Arthritis Care Res"},{"key":"111_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2147\/PPA.S97927","volume":"11","author":"T Aung","year":"2017","unstructured":"Aung T, Myung G, FitzGerald JD. Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient Prefer Adherence. 2017;11:795\u2013800.","journal-title":"Patient Prefer Adherence"},{"key":"111_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925\u201334.","journal-title":"Mayo Clin Proc"},{"key":"111_CR23","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1185\/03007990903017966","volume":"25","author":"R Halpern","year":"2009","unstructured":"Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25:1711\u20139.","journal-title":"Curr Med Res Opin"},{"key":"111_CR24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.140588","volume":"42","author":"N Rashid","year":"2015","unstructured":"Rashid N, Coburn BW, Wu YL, et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol. 2015;42:504\u201312.","journal-title":"J Rheumatol"},{"key":"111_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","volume":"20","author":"HS Baraf","year":"2014","unstructured":"Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014;20:427\u201332.","journal-title":"J Clin Rheumatol"},{"key":"111_CR26","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60.","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-018-0111-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-018-0111-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-018-0111-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T02:48:22Z","timestamp":1751597302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-018-0111-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1007\/s40744-018-0111-9","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,3]]},"assertion":[{"value":"26 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}